Intro As I continue the series of articles on the projects we specialize in at SiVan Consulting, I thought I would tackle
Intro This is the second article discussing how to run a benchmarking project. If you haven’t read the first, in which we
Getting a Nature + subscription was one of the best decisions we made this year. For £15 a month we get access
When you read the Pharma news sites and analysis on LinkedIn about drug patent cliffs, you might think pharmaceutical companies are sitting
With the sun out and a few projects wrapping up, I have enjoyed longer dog walks and catching up on new pharmaceutical
Introduction: Spotting the Threat You Didn’t Expect This week’s article is based on a project I completed earlier this year as part
Early this week, I joined Chris Spivey on PharmaTech.com’s Behind the Headlines to discuss several of the previous week’s significant life science
~1.5 years ago I was reading a Financial Times article (FT.com) on obesity drugs and their order to market when my critical
Following last week’s post on the slow activity in M&A in 2025 so far (Sivan-Consulting), we now have some activity picking up,
It has been a bit of a writing hiatus as I have been in the middle of delivering a few short, intense
This post/article is worth a read for those interested in the evolution of Pharma Business models: Pharma Exec – The Teva Turnaround
This follows last week’s post (Link) on the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companies, based
I recently read an interesting paper from Prof. Alexander Schuhmacher et al. on the impact of M&A and licensing on FDA drug
1. Introduction In this project history, I’ll talk about an example of a proactive company preparing for an event several years away,
If you have decided to do a benchmarking exercise and collected a load of data, including primary research, you’re now probably thinking,